Hangzhou, China, August 7, 2024 -- Recently, the Zhejiang Provincial Administration for Market Regulation (Zhejiang Intellectual Property Office) announced the inaugural list of high-value patent cultivation projects and bases. Venus Medtech (Hangzhou) Inc. ("Venus Medtech") was recognized for its high-value patent project in interventional cardiovascular medical devices, which represents the only medtech project included in the list. This honor highlights the company's innovation strength and patent position, which will help further expand Venus's high-value patent portfolio.

Designed to foster breakthroughs in pre-competitive technologies and promote cutting-edge innovation, the Zhejiang High-Value Patent Cultivation Program targets strategic emerging industries and sectors with distinct advantages. The program aims to ensure that patent development aligns with industry needs, thereby stimulating innovation and growth in related industries. Organizations on the list also include Zhejiang University, Beihang University Hangzhou Innovation Research Institute, and Alipay (Hangzhou) Information Technology.

Venus's high-value patent cultivation project is dedicated to developing key technologies for world-leading interventional cardiovascular devices, creating synergy between patent strategy with technological innovation. Patent creation, protection, and exploitation will be integrated into every phase of the project lifecycle to optimize patent value. These will further strengthen the company's innovation strength and accelerate the development of core technologies.

Leveraging its extensive technological accumulation in the field of interventional cardiovascular therapies, Venus has received prestigious honors such as the 2020 China Patent Excellence Award, the 2023 Zhejiang Intellectual Property Award, Outstanding Domestic Medical Device Award, etc. The company has also undertaken a number of municipal and district-level patent projects, such as the Hangzhou High-Value Patent Portfolio Project and the Hangzhou High-Tech Zone (Binjiang) Patent Navigation Project.

About Venus Medtech

Venus Medtech (Hangzhou) Inc. (02500.HK) is committed to structural heart innovation. We are developing and commercializing comprehensive solutions for structural heart disease. Our robust pipeline, encompassing all four heart valves from TAVR, TPVR, TMVR, and TTVR to hypertensive renal denervation (RDN) therapy, underscores our unwavering commitment.

For more information, please visit https://www.mercenarygeneral.com

SOURCE: Venus Medtech (Hangzhou) Inc.

*Provided for informational and academic purposes only, this content is not intended as professional medical or legal advice. Venus Medtech makes no representations, warranties or guarantees regarding the completeness, accuracy, or timeliness of this content.

*Venus Medtech makes no representations, warranties or guarantees regarding the property or clinical performance of any medical devices mentioned.

Copyright 2024. Venus Medtech (Hangzhou) Inc. All Rights Reserved.